Joe Jimenez (Steffen Schmidt/Keystone via AP Images)

Joe Jimenez forges an­oth­er big-mar­ket, small-cash deal, lin­ing up a kid­ney dis­ease drug for his lat­est port­fo­lio start­up

Ex-No­var­tis CEO Joe Jimenez and his part­ner Mark Fish­man put to­geth­er a $133 mil­lion fund to back their play at Adi­tum, look­ing to add se­lect …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.